Christian Posch M.D. Ph.D. - dermatologist

Head of dermato-oncology, Technical University of Munich

The Posch-lab focuses on skin cancer biology and inflammatory skin diseases.

Dr. Posch is a board certified physician scientist with ten years of experience in clinical dermatology and substantial productivity in melanoma and basic cancer research. In previous studies, he has highlighted the critical role of the MAPK, PI3K/AKT/mTOR and cell cycle pathways for NRAS mutant melanoma maintenance. His clinical responsibilities include the management of patients with cutaneous neoplasms and complex dermatological diseases. He just recently joined the team of the Department for Dermatology at the Technical University of Munich (Klinikum rechts der Isar) to head the sub-division Dermato-Oncology.

 

The Posch-lab is convinced that it is necessary to combine targeted inhibition, immunotherapy and new technologies for successful cancer therapy. It is thus our goal to characterize proteomic and (epi)genetic denominators of response to current therapeutic modalities, in an effort to discover novel strategies for improved efficacy of cancer treatments.

 

Antonia Wiala M.D. - resident in dermatology

Rudolfstiftung Hospital, Vienna

Current clinical and study activities

 

Sept 2017 – Nov 2018              Study coordinator HARMONY Study (abbvie)

 

May 2017 – present                  Hidradenitis suppurativa specialized clinic

                                                    Rudolfstiftung and study coordinator

 

 Current projects:

                              

Valentin Rauca Ph.D. - molecular biologist

Technical University of Munich, Munich

Allergy and Immunology Research Group

Mr. Rauca is a molecular biologist with specific expertise in melanoma cancer research. In his previous work, he has focused on developing tumor-targeted therapies by exploiting tumor intercellular communication tools, especially the interplay between tumor cells and tumor-associated macrophages (TAMs). His technical skills in the fields of proteomics, biochemistry, RNA analysis and nanoparticle preparation are the core asset in our efforts to elucidate the molecular mechanisms of melanoma development, progression and resistance to therapy.

 

 Current projects:

                              

Constanze Kainz M.Sc. - biochemist

Technical University of Munich, Munich

Ms. Kainz is a molecular biochemist of the Technical University of Munich with a focus on oncology and additional expertise in human medicine. In her Master’s studies she investigated the NF-κB signaling pathway and the influence of Hsp27 on cancer cell physiology. Her practical research experience includes the CRISPR/Cas9 technology and live single-cell imaging. She just recently joined the Posch-lab as a PhD student to specialize in the field of melanoma research.

 

During her PhD studies she will address the underlying mechanisms leading to senescence-escape in early melanoma development. As a member of the Posch-lab, it is her motivation that scientific findings on this project will lead to the development of new therapeutic approaches to improve the treatment of melanoma patients.

 Current projects:

                              

  • The role of senescence-escape in early melanoma development

Wilson Liao M.D. - dermatologist

University of California San Francisco, CA, USA

ACADEMIC INTERESTS
Dr. Liao serves as Director of the UCSF Psoriasis and Skin Treatment Center and is deeply engaged in patient care, clinical trials, and basic science research. The Liao laboratory studies the genetics and environmental triggers of psoriasis, a common immune-mediated skin disease. Dr. Liao directs the UCSF Psoriasis Research Initiative and Biobank with over 1,000 subjects, which is used for genetic and translational research studies.

 

The Liao lab has contributed to the publication of the first two genome-wide association studies in psoriasis and has helped identify over 20 additional risk variants. His lab has identified a genetic similarity between individuals with psoriasis and individuals who have robust immunity against HIV-1. This has highlighted the role of antiviral immune responses in contributing to autoimmune susceptibility.

Collaboration with the POSCHlab:

- Genetics of Hidradenitis suppurativa 

Richard Ahn Ph.D. 

Institute for Quantitative and Computational Biosciences  

University of California Los Angeles, CA, USA

ACADEMIC INTERESTS
 

Collaboration with the POSCHlab:

- Genetics of Hidradenitis suppurativa 

Prof. Klemens Rappersberger M.D. - dermatologist

Krankenanstalt Rudolfstiftung, Vienna, Austria

ACADEMIC INTERESTS

Prof. Rappersberger is a distinguished dermatologist and dermato-pathologist. He currently heads the department for Dermatology and Venereology at the Krankenanstalt Rudolfstiftung in Vienna, Austria. 

Prof. Rappersberger has contributed to over 130 scientific publications in high ranking journals. His work has made him one of the most established Austrian physicians in the treatment of complex dermatologic diseases, particularly bullous skin disorders. Like no other, he combines  his profound dermato-pathologic knowledge and over 35 years of clinical experience to provide excellence in patient care and science.  

Collaboration with the POSCHlab:

- Genetics of Hidradenitis suppurativa

- Hidradenitis suppurativa disease activity score 

- The role of senescence-escape in early melanoma develoment

- IM.A.RAS 

© 2020 by Posch-lab

Video by Alex T.Ritter/NIH Oxford-Cambridge Scholars